SPY342.73-0.65 -0.19%
DIA281.97-0.98 -0.35%
IXIC11,484.69-31.80 -0.28%

Morphic Announces Presentation of New Data Supporting Development of MORF-057 at UEG Week Virtual 2020

Data validate physiologically relevant assay used in MORF-057 Phase 1 studies to measure receptor occupancy of α4β7 integrin MORF-057, inhibitor of α4β7 integrin, in development to treat

· 10/12/2020 07:06
  • Data validate physiologically relevant assay used in MORF-057 Phase 1 studies to measure receptor occupancy of α4β7 integrin
  • MORF-057, inhibitor of α4β7 integrin, in development to treat inflammatory bowel disease